NDAORALFOR SUSPENSION
Approved
Aug 2009
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
14
Data completeness
6/8 — Strong
RENVELA (sevelamer carbonate) by Sanofi is non-absorbed phosphate-binding cross-linked polymer, free of metal and calcium. Approved for hyperphosphatemia, chronic kidney disease, end stage renal disease. First approved in 2009.
Drug data last refreshed 20h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RENVELA (sevelamer carbonate) is an oral non-absorbed phosphate-binding polymer approved by the FDA in 2009 for managing hyperphosphatemia in patients with chronic kidney disease on dialysis. The drug works by binding phosphate in the gastrointestinal tract through ionic and hydrogen bonding interactions, thereby reducing serum phosphorus levels without requiring metal or calcium as binding agents. As a unique mechanism phosphate binder, RENVELA represents an important alternative in the management of mineral and bone disorder in dialysis populations.
$0.1BPart D
4.6 years to LOEMechanism of Action
non-absorbed phosphate-binding cross-linked polymer, free of metal and calcium. It contains multiple amines separated by one carbon from the polymer backbone. These amines exist in a protonated form in the intestine and interact with phosphate molecules through ionic and hydrogen bonding. By…
Indications (3)
Worked on RENVELA at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.